Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

OWC Pharmaceutical Corporation Advisory Board Member, Jeffrey Friedland, Comments on the Election and the Possible Impact on the U.S. Cannabis Market

OWC Pharmaceutical Research Corp.
Posted on: 07 Nov 16

PR Newswire

PETACH TIKVA, Israel, November 7, 2016

PETACH TIKVA, Israel, November 7, 2016 /PRNewswire/ --

OWC Pharmaceutical Research Corp. (OTCQB: OWCP), through its Israeli based fully owned subsidiary, (collectively "OWC" or the "Company") a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, was featured in the comments of its Advisory Board member, Jeffrey Friedland. In addition to serving on the Company's Advisory Board, Mr. Friedland is the Chief Executive Officer of Intiva Inc., author of Marijuana: The World's Most Misunderstood Plant, and frequent keynote speaker for the cannabis industry.

     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-a )


     (Logo: http://photos.prnewswire.com/prnh/20150311/734965-b )

Recently, Mr. Friedland commented on the pending election and the possible effects on the future of the cannabis industry, "Many entrepreneurs and investors have expressed their concerns to me regarding the outcome of Tuesday's U.S. presidential election, specifically whether the winner will have a positive or negative impact on the cannabis industry. Both Hillary Clinton and Donald Trump have stated that they will support the medical use of cannabis."

Mr. Friedland went on to say, "Regardless of the outcome of Tuesday's vote, I see no immediate change in the existing system of allowing state-licensed medical cannabis businesses, nor do I see any immediate change in the rescheduling of cannabis under the Controlled Substances Act…..What is more significant to the U.S. cannabis industry is Tuesday's outcome of voting in California and Nevada, where adult recreational use of cannabis is on the ballot. I'm expecting voters in both states to approve recreational cannabis."

Regarding Intiva's investment in OWC, Mr. Friedland had this to say, "The decision to invest in OWC during the summer of 2014 came after spending some time in Israel, where I concluded that the real money in the cannabis industry will be made by companies who create 'real pharmaceuticals based on real science.' I was impressed with OWC's management team; Dr. Yehuda Baruch, the Company's director of research, was the former head of Israel's medical cannabis program. I also found intriguing the early-stage research OWC had underway regarding trials of their proprietary cannabis-based formulations for the treatment of multiple myeloma and other conditions."

As for the potential effect of the election on OWC, Mr. Friedland added that if, as he expected, California and Nevada approved recreational cannabis, the Company had "plenty to gain from Tuesday's vote in the U.S……as OWC Pharmaceutical Research recently announced that it has entered into a U.S. license agreement with a Maryland-based company to bring its topical psoriasis cream to state-licensed businesses in the U.S. market….and the establishment of recreational cannabis businesses in California and Nevada would significantly increase the availability of medical cannabis for patients in those states.

About OWC Pharmaceutical Research Corp.    

OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively "OWC" or the "Company") conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.

The Company's Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks. For more information, visit: http://www.owcpharma.com/

About Jeffrey Friedland 

Jeffrey Friedland is an emerging market pioneer -- his firm, Friedland Global Capital, was one of the first American investment banks to establish a presence in China -- and he can now be found on the forefront of the cannabis movement. In his book, Marijuana: The World's Most Misunderstood Plant guides the reader through the plant's rich, and sometimes scandalous history, explains how and why cannabis affects us, describes the methods of breeding, cultivating and processing that plant, and perhaps most importantly, gives an overview of the most recent research into its potential within the word of medicine.

Mr. Friedland was an owner of two retail cannabis stores in Colorado in the mountain resort towns of Breckenridge and Crested Butte, and a cannabis cultivation facility located south of Steamboat Springs, which were featured in CNN's 2015 reality series, High Profits. He is also CEO of INTIVA Inc., a multi-faceted life sciences company in the worldwide legal cannabis industry. INTIVA has established operating businesses and made venture investments in the cannabis industry in California, Colorado, Canada and Israel.

Mr. Friedland is also CEO of the financial services firm Friedland Global Capital, which provides corporate finance and strategic advisory services to entrepreneurial companies in emerging markets. He has been the CEO of a Nasdaq-listed company, a member of the board of directors and chairman of the audit committee of a New York Stock Exchange-listed company, and the chairman of the supervisory board of a company listed on the Regulated Market of the Frankfurt Stock Exchange. Mr. Friedland has been featured, interviewed or quoted in numerous publications including the Wall Street Journal, USA Today, The South China Morning Post (Hong Kong), NBC.com, Forbes, CNBC and its predecessor, Financial News Network, Bloomberg Information Radio, and Bloomberg TV. This is the second book he has written. All Roads Lead to China: An Investor Road Map to the World's Fastest Growing Economy was published in 2014.

Notice Regarding Forward-Looking Statements   

This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, filing patent applications, product development, and business strategy. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in OWC Pharmaceutical Research Corp. (OTCQB: OWCP) periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact Information:
In Israel
Ziv Turner, Chief Executive Officer - One World Cannabis Ltd.
Email: ziv.turner@owcpharma.com
Tel: +972(0)3-7582659

SOURCE OWC Pharmaceutical Research Corp.

PR Newswire
www.prnewswire.com

Last updated on: 07/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.